JPMorgan Chase & Co. Issues Positive Forecast for Twist Bioscience (NASDAQ:TWST) Stock Price

Twist Bioscience (NASDAQ:TWST) had its target price boosted by JPMorgan Chase & Co. from $35.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has an underweight rating on the stock.

TWST has been the subject of several other reports. Barclays lowered their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, Scotiabank raised their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and a consensus target price of $53.80.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $52.02 on Tuesday. The company has a market capitalization of $3.09 billion, a price-to-earnings ratio of -14.45 and a beta of 1.87. Twist Bioscience has a 1-year low of $27.41 and a 1-year high of $60.90. The business has a 50-day moving average of $48.63 and a 200-day moving average of $46.21.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period last year, the firm earned ($0.75) earnings per share. The company’s revenue was up 24.1% on a year-over-year basis. Research analysts expect that Twist Bioscience will post -2.27 EPS for the current fiscal year.

Insider Buying and Selling

In other Twist Bioscience news, COO Patrick John Finn sold 10,340 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $496,320.00. Following the completion of the sale, the chief operating officer now directly owns 221,061 shares of the company’s stock, valued at $10,610,928. The trade was a 4.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Paula Green sold 860 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $45,322.00. Following the completion of the sale, the senior vice president now owns 133,715 shares of the company’s stock, valued at $7,046,780.50. This represents a 0.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,707 shares of company stock valued at $2,343,623. Corporate insiders own 3.01% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA boosted its holdings in shares of Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after buying an additional 20,035 shares during the period. Barclays PLC raised its position in Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after purchasing an additional 104,420 shares in the last quarter. FMR LLC lifted its position in shares of Twist Bioscience by 6.0% during the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock worth $9,875,000 after buying an additional 12,327 shares during the period. Avanza Fonder AB bought a new position in shares of Twist Bioscience during the fourth quarter valued at $1,059,000. Finally, BNP Paribas Financial Markets boosted its position in Twist Bioscience by 128.1% in the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after buying an additional 21,357 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.